Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?
Differentiated thyroid cancer
Radioactive iodine therapy
Sialadenitis
Xerostomia
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
10
12
2020
accepted:
31
05
2021
pubmed:
19
6
2021
medline:
1
3
2022
entrez:
18
6
2021
Statut:
ppublish
Résumé
This study aims to elaborate on the current knowledge concerning the mechanism, frequency, clinical manifestations, diagnostic procedures, prevention, and management of radioactive iodine (RAI)-induced sialadenitis in patients receiving treatment for differentiated thyroid cancer (DTC). A review of the literature was carried out through the " www.ncbi.nlm.nih.gov/pubmed " database focusing on the results of the past decade. The high concentration of RAI in the salivary glands results in high beta radiation exposure of the striated duct cells and stem cells. This exposure leads to acute and/or chronic sialadenitis with obstructive symptoms and progressive loss of salivary gland function and xerostomia, with severe impact on patients' quality of life. No standard diagnostic method has been established. As far as prevention is concerned, many approaches have been proposed, such as sialogogues, local massage, vitamin E, and amifostine administration. Although there is no unanimity as to their effectiveness, the use of sialogogues is recommended. Treatment includes conservative drug therapy and sialendoscopy when necessary. RAI-induced sialadenitis has a major impact on patients' quality of life. Due to the good prognosis of DTC, the reduction of sialadenitis and its prognosis, prevention, and treatment constitute a priority for the overall treatment of these patients. Further studies that will establish a coherent treatment protocol for this condition are necessary.
Identifiants
pubmed: 34143403
doi: 10.1007/s42000-021-00304-3
pii: 10.1007/s42000-021-00304-3
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
669-678Informations de copyright
© 2021. Hellenic Endocrine Society.
Références
Haugen BR, Alexander E, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 1:1–133. https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020
Hesselink EN, Links TP (2015) Radioiodine treatment and thyroid hormone suppression therapy for differentiated thyroid carcinoma: adverse effects support the trend toward less aggressive treatment for low-risk patients. Eur Thyroid J 4:82–92. https://doi.org/10.1159/000432397
doi: 10.1159/000432397
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E, European Association of Nuclear Medicine (EANM) (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959. https://doi.org/10.1007/s00259-008-0883-1
doi: 10.1007/s00259-008-0883-1
pubmed: 18670773
Aktaş A, Kavak K, Kocabaş B, Aras M, Tütüncü NB, Gençoğlu A (2008) The biodistribution of radioiodine on posttherapy iodine131 scans in thyroid cancer patients with chronic renal failure. Nucl Med Commun 29:943–948. https://doi.org/10.1097/MNM.0b013e32831089e0
doi: 10.1097/MNM.0b013e32831089e0
pubmed: 18836371
Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE (1999) Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 84:4178–4184. https://doi.org/10.1210/jcem.84.11.6117
doi: 10.1210/jcem.84.11.6117
pubmed: 10566669
da Fonseca FL, Yamanaka PK, Mazoti L, Arakawa-Sugueno L, Kato JM, Matayoshi S (2017) Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: a prospective comparative study. Head Neck 39:2381–2396. https://doi.org/10.1002/hed.24895
doi: 10.1002/hed.24895
pubmed: 28945293
Silberstein EB (2008) Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. Randomized Controlled Trial J Nucl Med 49(4):546–549. https://doi.org/10.2967/jnumed.107.049411
doi: 10.2967/jnumed.107.049411
pubmed: 18344428
La Perle KM, Kim DC, Hall NC, Bobbey A, Shen DH, Paul NRS, Wakely E Jr, Lehman A, Jarjoura D, Jhiang SM (2013) Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid 23:1029–1036. https://doi.org/10.1089/thy.2012.0571
doi: 10.1089/thy.2012.0571
pubmed: 23441638
pmcid: 3752512
Holmberg KV, Hoffman MP (2014) Anatomy, biogenesis and regeneration of salivary glands. Monogr Oral Sci 24:1–13. https://doi.org/10.1159/000358776
doi: 10.1159/000358776
pubmed: 24862590
pmcid: 4048853
Van Nostrand D (2011) Sialoadenitis secondary to
doi: 10.1111/j.1601-0825.2010.01726.x
pubmed: 21029259
Hong CM, Son SH, Kim CY, Kim DH, Jeong SY, Lee SW, Lee J, Ahn BC (2014) Emptying effect of massage on parotid gland radioiodine content. Nucl Med Commun 35:1127–1131. https://doi.org/10.1097/MNM.0000000000000176
doi: 10.1097/MNM.0000000000000176
pubmed: 25121980
Kim YM, Choi JS, Hong SB, Hyun IY, Lim JY (2016) Salivary gland function after sialendoscopy for treatment of chronic radioiodine-induced sialadenitis. Head Neck 38:51–58. https://doi.org/10.1002/hed.23844
doi: 10.1002/hed.23844
pubmed: 24995941
Liu B, Kuang A, Huang R, Zhao Z, Zeng Y, Wang J, Tian R (2010) Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial. J Nucl Med 51(4):618–623. https://doi.org/10.2967/jnumed.109.071449
doi: 10.2967/jnumed.109.071449
pubmed: 20237029
Riachy R, Ghazal N, Haidar MB, Elamine A, Nasrallah MP (2020) Early sialadenitis after radioactive iodine therapy for differentiated thyroid cancer: prevalence and predictors. Int J Endocrinol 2020:8649794. https://doi.org/10.1155/2020/8649794
doi: 10.1155/2020/8649794
pubmed: 33163074
pmcid: 7604595
Hollingsworth B, Senter L, Zhang X et al (2016) Risk factors of
doi: 10.1210/jc.2016-1605
pubmed: 27533304
pmcid: 5095242
Alotaibi H, Tuzlakoğlu-Öztürk M, Tazebay UH (2017) The thyroid Na+/I- symporter: molecular characterization and genomic regulation. Mol Imaging Radionucl Ther 26:92–101. https://doi.org/10.4274/2017.26.suppl.11
doi: 10.4274/2017.26.suppl.11
pubmed: 28117294
pmcid: 5283716
Koca G, Gültekin SS, Han U, Kuru S, Demirel K, Korkmaz M (2013) The efficacy of montelukast as a protective agent against 131I-induced salivary gland damage in rats: scintigraphic and histopathological findings. Nucl Med Commun 34:507–517. https://doi.org/10.1097/MNM.0b013e32835ffecd
doi: 10.1097/MNM.0b013e32835ffecd
pubmed: 23478587
Kim JW, Kim JM, Choi ME, Kim SK, Kim YM, Choi JS (2020) Does salivary function decrease in proportion to radioiodine dose? Laryngoscope 130(9):2173–2178. https://doi.org/10.1002/lary.28342
doi: 10.1002/lary.28342
pubmed: 31765488
Tateishi Y, Sasabe E, Ueta E, Yamamoto T (2008) Ionizing irradiation induces apoptotic damage of salivary gland acinar cells via NADPH oxidase 1-dependent superoxide generation. Biochem Biophys Res Commun 366:301–307. https://doi.org/10.1016/j.bbrc.2007.11.039
doi: 10.1016/j.bbrc.2007.11.039
pubmed: 18035043
Avila JL, Grundmann O, Burd R, Limesand KH (2009) Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis. Int J Radiat Oncol Biol Phys 73:523–529. https://doi.org/10.1016/j.ijrobp.2008.09.036
doi: 10.1016/j.ijrobp.2008.09.036
pubmed: 19147016
pmcid: 2631421
Sadiç M, Korkmaz M, Gültekin SS, Demircan K (2016) Alterations in ADAMTS12 gene expression in salivary glands of radioiodine-131-administeredrats. Nucl Med Commun 37:1010–1015. https://doi.org/10.1097/MNM.0000000000000556
doi: 10.1097/MNM.0000000000000556
pubmed: 27295306
Choi JS, Park IS, Kim SK, Lim JY, Kim YM (2013) Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model. Thyroid 23:1445–1451. https://doi.org/10.1089/thy.2012.0243
doi: 10.1089/thy.2012.0243
pubmed: 23607283
pmcid: 3822387
Sadic M, Demirel K, Halacli SO, Karakok E, Koca G, Ekinci O, Demircan K, Korkmaz M (2018) Expression of ADAMTS2 and ADAMTS5 in the salivary gland of rats after radioiodine therapy. Nucl Med Commun 39:110–117. https://doi.org/10.1089/thy.2012.0243
doi: 10.1089/thy.2012.0243
pubmed: 29194287
Hesselink ENK, Brouwers AH, de Jong JR, van der Horst-Schrivers AN, Coppes RP, Lefrandt JD, Jager PL, Vissink A, Links TP (2016) Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma: a prospective study. J Nucl Med 57:1685–1691. https://doi.org/10.2967/jnumed.115.169888
doi: 10.2967/jnumed.115.169888
Selvakumar T, Nies M, Klein Hesselink MS, Brouwers AH, van der Horst-Schrivers ANA, Klein Hesselink EN, Tissing WJE, Vissink A, Links TP, Bocca G, Burgerhof JGM, van Dam EWCM, Havekes B, van den Heuvel-Eibrink MM, Corssmit EPM, Kremer LCM, Netea-Maier RT, van der Pal HJH, Peeters RP, Smit JWA, Plukker JTM, Ronckers CM, van Santen HM (2018) Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma. J Nucl Med. https://doi.org/10.2967/jnumed.118.212449
doi: 10.2967/jnumed.118.212449
pubmed: 30504138
Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR (2017) Salivary evaluation in radioactive I131 treated patients with thyroid carcinoma. Acta Odontol Scand 76:148–152. https://doi.org/10.1080/00016357.2017.1399214
doi: 10.1080/00016357.2017.1399214
pubmed: 29125000
Walter MA, Turtschi CP, Schindler C, Minnig P, Müller-Brand J, Müller B (2007) The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med 48:1620–1625. https://doi.org/10.2967/jnumed.107.042192
doi: 10.2967/jnumed.107.042192
pubmed: 17873131
Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J (2013) Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid 23(5):609–616. https://doi.org/10.1089/thy.2012.0106
doi: 10.1089/thy.2012.0106
pubmed: 23153322
pmcid: 3643252
Bhayani MK, Acharya V, Kongkiatkamon S, Farah S, Roberts DB, Sterba J, Chambers MS, Lai SY (2015) Sialendoscopy for patients with radioiodine-induced sialadenitis and xerostomia. Thyroid 25:834–838. https://doi.org/10.1089/thy.2014.0572
doi: 10.1089/thy.2014.0572
pubmed: 25860842
pmcid: 5118964
An YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo KS (2013) Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. Ann Nucl Med 27:386–391. https://doi.org/10.1007/s12149-013-0697-5
doi: 10.1007/s12149-013-0697-5
pubmed: 23389626
Lee HN, An JY, Lee KM, Kim EJ, Choi WS, Kim DY (2015) Salivary gland dysfunction after radioactive iodine (I131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose. Clin Imaging 39:396–400. https://doi.org/10.1016/j.clinimag.2014.12.018
doi: 10.1016/j.clinimag.2014.12.018
pubmed: 25630229
Erkul E, Gillespie MB (2016) Sialendoscopy for non-stone disorders: the current evidence. Laryngoscope Investig Otolaryngol 1:140–145. https://doi.org/10.1002/lio2.33
doi: 10.1002/lio2.33
pubmed: 28894810
pmcid: 5510257
Lu L, Shan F, Li W, Lu H (2016) Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer. Biomed Res Int. https://doi.org/10.1155/2016/4376720
doi: 10.1155/2016/4376720
pubmed: 28119929
pmcid: 5227127
Wu JQ, Feng HJ, Ouyang W, Sun YG, Chen P, Wang J, Xian JL, Huang LH (2015) Systematic evaluation of salivary gland damage following I131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. Nucl Med Commun 36:819–826. https://doi.org/10.1097/MNM.0000000000000325
doi: 10.1097/MNM.0000000000000325
pubmed: 25932534
De Luca R, Vicidomini A, Trodella M, Tartaro G, Colella G (2014) Sialoendoscopy: a viable treatment for I(131) induced sialoadenitis. Br J Oral Maxillofac Surg 52:641–646. https://doi.org/10.1016/j.bjoms.2014.01.025
doi: 10.1016/j.bjoms.2014.01.025
pubmed: 24894709
Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM (2009) Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 50(10):1605–1610. https://doi.org/10.2967/jnumed.108.061382
doi: 10.2967/jnumed.108.061382
pubmed: 19759114
Wu CB, Xi H, Zhou Q, Zhang LM (2015) Sialendoscopy-assisted treatment for radioiodine-induced sialadenitis. J Oral Maxillofac Surg 73:475–481. https://doi.org/10.1016/j.joms.2014.09.025
doi: 10.1016/j.joms.2014.09.025
pubmed: 25544300
Almeida JP, Sanabria AE, Lima EN, Kowalski LP (2011) Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 33:686–690. https://doi.org/10.1002/hed.21520
doi: 10.1002/hed.21520
pubmed: 21484917
Upadhyaya A, Meng Z, Wang P, Zhang G, Jia Q, Tan J, Li X, Hu T, Liu N, Zhou P, Wang S, Liu X, Wang H, Zhang C, Zhao F, Yan Z (2017) Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer. Medicine (Baltimore) 96(25):e7164. https://doi.org/10.1097/MD.0000000000007164
doi: 10.1097/MD.0000000000007164
Sasaki T, Nabaa B, Takahashi K, Okizaki A, Ishitoya S (2015) Non-contrast-enhanced computed tomography attenuation in the parotid glands before radioiodine therapy for thyroid carcinoma could be a predictor of radiovulnerability. Nucl Med Commun 36:350–355. https://doi.org/10.1097/MNM.0000000000000250
doi: 10.1097/MNM.0000000000000250
pubmed: 25501901
Jentzen W, Schneider E, Freudenberg L, Eising EG, Görges R, Müller SP, Brandau W, Bockisch A (2006) Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Nucl Med Commun 8:669–676. https://doi.org/10.1097/00006231-200608000-00009
doi: 10.1097/00006231-200608000-00009
Fallahi B, Beiki D, Abedi SM, Saghari M, Fard-Esfahani A, Akhzari F, Mokarami B, Eftekhari M (2013) Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? Nucl Med Commun 34:777–786. https://doi.org/10.1097/MNM.0b013e328362b1f2
doi: 10.1097/MNM.0b013e328362b1f2
pubmed: 23708871
Jonklaas J, Wang H, Esposito G (2015) Salivary function after radioiodine therapy: poor correlation between symptoms and salivary scintigraphy. Front Endocrinol (Lausanne) 6:100. https://doi.org/10.3389/fendo.2015.00100
doi: 10.3389/fendo.2015.00100
Jo KS, An YS, Lee SJ, Soh EY, Lee J, Chung YS, Kim DJ, Yoon SH, Lee DH, Yoon JK (2014) Significance of salivary gland radioiodine retention on post-ablation (131)I scintigraphy as a predictor of salivary gland dysfunction in patients with differentiated thyroid carcinoma. Nucl Med Mol Imaging 48:203–211. https://doi.org/10.1007/s13139-014-0274-4
doi: 10.1007/s13139-014-0274-4
pubmed: 25177377
pmcid: 4145088
Brozzi F, Rago T, Bencivelli W, Bianchi F, Santini P, Vitti P, Pinchera A, Ceccarelli C (2013) Salivary glands ultrasound examination after radioiodine-131 treatment for differentiated thyroid cancer. J Endocrinol Invest 36:153–156. https://doi.org/10.3275/8335
doi: 10.3275/8335
pubmed: 22522602
Nabaa B, Takahashi K, Sasaki T, Okizaki A, Aburano T (2012) Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands. AJNR Am J Neuroradiol 33:1964–1970. https://doi.org/10.3174/ajnr.A3063
doi: 10.3174/ajnr.A3063
pubmed: 22555571
pmcid: 7964601
Maruoka Y, Baba S, Isoda T, Kitamura Y, Abe K, Sasaki M et al (2017) A functional scoring system based on salivary gland scintigraphy for evaluating salivary gland dysfunction secondary to 131I therapy in patients with differentiated thyroid carcinoma. J Clin Diagn Res 11:TC23–TC28. https://doi.org/10.7860/JCDR/2017/27340.10431
doi: 10.7860/JCDR/2017/27340.10431
pubmed: 28969240
pmcid: 5620881
Ma C, Xie J, Jiang Z, Wang G, Zuo S (2010) Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:1778–1785. https://doi.org/10.1007/s00259-009-1368-6
doi: 10.1007/s00259-009-1368-6
pubmed: 20130857
Edwards O, Yakish ED, Wang LM, Wu Q, Hoffman JM, Morton KA (2015) Histamine receptor 1 and 2 antagonists alter biodistribution of radioiodine. J Nucl Med Technol 43:214–219. https://doi.org/10.2967/jnmt.115.160697
doi: 10.2967/jnmt.115.160697
pubmed: 26111706
Rosário PW, Borges MA, Purisch S (2008) Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776–1782. https://doi.org/10.2967/jnumed.108.050591
doi: 10.2967/jnumed.108.050591
pubmed: 18927337
Iakovou I, Goulis DG, Tsinaslanidou Z, Giannoula E, Katsikaki G, Konstantinidis I (2016) Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation. Head Neck 38(Suppl 1):E227-230. https://doi.org/10.1002/hed.23974
doi: 10.1002/hed.23974
pubmed: 25537365
Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47(4):648–654
pubmed: 16595499
Kulkarni K, Van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L (2014) Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun 35:210–216. https://doi.org/10.1097/MNM.0000000000000034
doi: 10.1097/MNM.0000000000000034
pubmed: 24177041
Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A (2010) The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 37:2298–2306. https://doi.org/10.1007/s00259-010-1532-z
doi: 10.1007/s00259-010-1532-z
pubmed: 20625723
Jentzen W, Richter M, Nagarajah J, Poeppel TD, Brandau W, Dawes C, Bockisch A, Binse I (2014) Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging. EJNMMI Phys 1:100. https://doi.org/10.1186/s40658-014-0100-1
doi: 10.1186/s40658-014-0100-1
pubmed: 26501458
pmcid: 4545453
Upadhyaya A, Zhou P, Meng Z, Wang P, Zhang G, Jia Q, Tan J, Li X, Hu T, Liu N, Wang S, Liu X, Wang H, Zhang C, Zhao F, Yan Z, Wang X, Zhang X, Zhang W (2017) Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial. Nucl Med Commun 38:891–903. https://doi.org/10.1097/MNM.0000000000000727
doi: 10.1097/MNM.0000000000000727
pubmed: 28806348
Bhartiya US, Raut YS, Joseph LJ, Hawaldar RW, Rao BS (2008) Evaluation of the radioprotective effect of turmeric extract and vitamin E in mice exposed to therapeutic dose of radioiodine. Indian J Clin Biochem 23:382–386. https://doi.org/10.1007/s12291-008-0084-5
doi: 10.1007/s12291-008-0084-5
pubmed: 23105792
pmcid: 3453134
Bhartiya US, Joseph LJ, Raut YS, Rao BS (2010) Effect of Ocimum sanctum, turmeric extract and vitamin E supplementation on the salivary gland and bone marrow of radioiodine exposed mice. Indian J Exp Biol 48:566–571
pubmed: 20882758
Choi JS, An HY, Park IS, Kim SK, Kim YM, Lim JY (2016) Radioprotective effect of epigallocatechin-3 gallate on salivary gland dysfunction after radioiodine ablation in a murine model. Clin Exp Otorhinolaryngol 9:244–251. https://doi.org/10.21053/ceo.2015.01011
doi: 10.21053/ceo.2015.01011
pubmed: 27136365
pmcid: 4996107
Saylam G, Bayır Ö, Gültekin SS, Pınarlı FA, Han Ü, Korkmaz MH (2017) Protective/restorative role of the adipose tissue-derived mesenchymal stem cells on the radioiodine-induced salivary gland damage in rats. Radiol Oncol 51:307–316. https://doi.org/10.1515/raon-2017-0022
doi: 10.1515/raon-2017-0022
pubmed: 28959167
pmcid: 5611995
Kim JW, Kim JM, Choi ME, Kim SK, Kim YM, Choi JS (2019) Adipose-derived mesenchymal stem cells regenerate radioiodine-induced salivary gland damage in a murine model. Sci Rep. https://doi.org/10.1038/s41598-019-51775-9
doi: 10.1038/s41598-019-51775-9
pubmed: 31892717
pmcid: 6938486
Kim JW, Han GS, Lee SH, Lee DY, Kim YM (2007) Sialoendoscopic treatment for radioiodine induced sialadenitis. Laryngoscope 117:133–136. https://doi.org/10.1097/01.mlg.0000247776.72484.62
doi: 10.1097/01.mlg.0000247776.72484.62
pubmed: 17202942
Prendes BL, Orloff LA, Eisele DW (2012) Therapeutic sialendoscopy for the management of radioiodine sialadenitis. Arch Otolaryngol Head Neck Surg 138:15–19. https://doi.org/10.1001/archoto.2011.215
doi: 10.1001/archoto.2011.215
pubmed: 22249623
Bomeli SR, Schaitkin B, Carrau RL, Walvekar RR (2009) Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. Laryngoscope 119:864–867. https://doi.org/10.1002/lary.20140
doi: 10.1002/lary.20140
pubmed: 19266587
Geres AE, Mereshian PS, Fernández S, Rey Caro DG, Castro R, Podio R, Ojeda S (2015) Sialadenitis after radioiodine therapy. Analysis of factors that influence the response to medical treatment. Endocrinol Nutr 62:493–498. https://doi.org/10.1016/j.endonu.2015.07.006
doi: 10.1016/j.endonu.2015.07.006
pubmed: 26459118
Strychowsky JE, Sommer DD, Gupta MK, Cohen N, Nahlieli O (2012) Sialendoscopy for the management of obstructive salivary gland disease: a systematic reviewand meta-analysis. Arch Otolaryngol Head Neck Surg 138:541–547. https://doi.org/10.1001/archoto.2012.856
doi: 10.1001/archoto.2012.856
pubmed: 22710505
Canzi P, Cacciola S, Capaccio P, Pagella F, Occhini A, Pignataro L, Benazzo M (2017) Interventional sialendoscopy for radioiodine-induced sialadenitis: quo vadis? Acta Otorhinolaryngol Ital 37:155–159. https://doi.org/10.14639/0392-100X-1606
doi: 10.14639/0392-100X-1606
pubmed: 28516979
pmcid: 5463524